Stocks
Geron CorporationGERN
NASDAQHealthcareBiotechnology$0.87
Price as of · delayed, not real-time
A biopharmaceutical company focused on developing therapies for hematologic malignancies, with its lead product Rytelo (imetelstat) approved for lower-risk myelodysplastic syndromes. Investors track it for its commercial ramp and pipeline expansion in blood cancers.
52W Range: $0.84-$2.01
Congressional Interest in Geron Corporation (GERN)
1 member of Congress has disclosed 1 trade in Geron Corporation (GERN), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading GERN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2004-12-10 | EDWARD R. ROYCE | sell | $1K-$15K |